155 related articles for article (PubMed ID: 18663410)
1. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.
Gullo G; Bettio D; Torri V; Masci G; Salvini P; Santoro A
Invest New Drugs; 2009 Apr; 27(2):179-83. PubMed ID: 18663410
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Han HS; Kim JS; Park JH; Jeon YK; Lee KW; Oh DY; Kim JH; Park SY; Im SA; Kim TY; Park IA; Bang YJ
J Korean Med Sci; 2009 Oct; 24(5):910-7. PubMed ID: 19794992
[TBL] [Abstract][Full Text] [Related]
3. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
[TBL] [Abstract][Full Text] [Related]
4. Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy.
Gullo G; Bettio D; Zuradelli M; Masci G; Giordano L; Bareggi C; Tomirotti M; Salvini P; Runza L; La Verde N; Santoro A
Breast; 2013 Apr; 22(2):190-193. PubMed ID: 23473771
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
Mass RD; Press MF; Anderson S; Cobleigh MA; Vogel CL; Dybdal N; Leiberman G; Slamon DJ
Clin Breast Cancer; 2005 Aug; 6(3):240-6. PubMed ID: 16137435
[TBL] [Abstract][Full Text] [Related]
6. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
8. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
9. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
11. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
13. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
14. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
Perez EA; Roche PC; Jenkins RB; Reynolds CA; Halling KC; Ingle JN; Wold LE
Mayo Clin Proc; 2002 Feb; 77(2):148-54. PubMed ID: 11838648
[TBL] [Abstract][Full Text] [Related]
15. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
[TBL] [Abstract][Full Text] [Related]
16. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
[TBL] [Abstract][Full Text] [Related]
17. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
Bates M; Sperinde J; Köstler WJ; Ali SM; Leitzel K; Fuchs EM; Paquet A; Lie Y; Sherwood T; Horvat R; Singer CF; Winslow J; Weidler JM; Huang W; Lipton A
Ann Oncol; 2011 Sep; 22(9):2014-2020. PubMed ID: 21289364
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ; Press M
J Clin Oncol; 2002 Feb; 20(3):719-26. PubMed ID: 11821453
[TBL] [Abstract][Full Text] [Related]
20. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.
Takahashi M; Inoue K; Goto R; Tamura M; Taguchi K; Takahashi H; Suzuki H; Katsushige K; Ogita M
Breast Cancer; 2003; 10(2):170-4. PubMed ID: 12736573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
